Q3 EPS Estimates for Gilead Sciences Increased by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Zacks Research raised their Q3 2026 earnings estimates for shares of Gilead Sciences in a report issued on Wednesday, November 20th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will post earnings per share of $2.18 for the quarter, up from their prior estimate of $2.11. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.38 per share.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $2.29 EPS.

A number of other brokerages have also recently issued reports on GILD. Mizuho increased their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday. Royal Bank of Canada increased their target price on shares of Gilead Sciences from $81.00 to $84.00 and gave the stock a “sector perform” rating in a research report on Monday. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective for the company. UBS Group raised their price objective on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $74.00 to $96.00 in a research report on Monday, October 21st. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $95.41.

Gilead Sciences Trading Up 1.4 %

Shares of Gilead Sciences stock opened at $89.84 on Friday. The stock has a market capitalization of $111.96 billion, a P/E ratio of 998.22, a price-to-earnings-growth ratio of 2.72 and a beta of 0.17. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a 50-day simple moving average of $87.28 and a 200 day simple moving average of $76.61. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $98.90.

Institutional Trading of Gilead Sciences

Institutional investors have recently made changes to their positions in the business. nVerses Capital LLC bought a new stake in shares of Gilead Sciences in the third quarter worth $25,000. Valued Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares in the last quarter. CarsonAllaria Wealth Management Ltd. lifted its position in shares of Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the second quarter worth $33,000. Finally, Cedar Wealth Management LLC lifted its position in shares of Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 56,947 shares of company stock valued at $4,968,674. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.43%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.